{
    "name": "blinatumomab",
    "comment": "Rx",
    "other_names": [
        "Blincyto"
    ],
    "classes": [
        "Bispecific T-Cell Engager (BiTE) Antibodies"
    ],
    "source": "https://reference.medscape.com/drug/blincyto-blinatumomab-999984",
    "pregnancy": {
        "common": [
            "Based on mechanism of action, therapy may cause fetal harm when administered to pregnant woman; verify pregnancy status of females of reproductive potential prior to initiating treatment",
            "Due to potential for B-cell lymphocytopenia in infants following exposure to blinatumomab in-utero, monitor infant’s B lymphocytes before the initiation of live virus vaccination",
            "Advise females of reproductive potential to use effective contraception during treatment and for at least 48 hr after the last dose of blinatumomab"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There is no information regarding presence of blinatumomab in human milk, effects on breastfed infant, or effects on milk production; because many drugs are excreted in human milk and because of potential for serious adverse reactions in nursing infants from therapy, including B-cell lymphocytopenia, advise patients not to breastfeed during and for at least 48 hr after ending therapy"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Cytokine release syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving blinatumomab; interrupt or discontinue depending on severity (see Dosage Modifications)",
                "Neurological toxicities, which may be severe, life-threatening, or fatal, occurred in patients receiving blinatumomab; interrupt or discontinue depending on severity (see Dosage Modifications)"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to blinatumomab or any components of product formulation"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Cytokine release syndrome (CRS), which may be life-threatening or fatal, has been observed and may be clinically indistinguishable from infusion reactions; serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased ALT, increased AST, and increased total bilirubin; monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), and total blood bilirubin prior to start of and during treatment (see Black Box Warnings)",
                "Neurological toxicities have occurred in ~65% of patients; median time to first event was within the first 2 weeks of treatment and majority of events resolved; ≥Grade 3 (severe, life-threatening, or fatal) neurological toxicities occurred in ~13% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders",
                "Serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal",
                "Tumor lysis syndrome may be life-threatening or fatal; appropriate prophylactic measures, including pretreatment nontoxic cytoreduction and on-treatment hydration, should be used for prevention: may require either temporary interruption or discontinuation",
                "Neutropenia and febrile neutropenia, including life-threatening cases, observed; monitor WBC and absolute neutrophil counts during infusion; interrupt if prolonged neutropenia occurs",
                "Owing to the potential for neurologic events, including seizures, patients are at risk for loss of consciousness; advise patients to refrain from driving and engaging in hazardous occupations or activities such as operating heavy or potentially dangerous machinery during treatment",
                "Transient elevation of liver enzymes reported; interrupt if the transaminases rise to >5 xULN or if bilirubin rises to >3 xULN",
                "Leukoencephalopathy observed confirmed by cranial MRI, especially in patients with prior treatment with cranial irradiation and antileukemic chemotherapy (high dose methotrexate, IT cytarabine); clinical significance of this is unknown",
                "Preparation and administration errors have occurred; follow instructions for preparation (including admixing) and administration strictly to minimize medication errors",
                "Potential for immunogenicity (as with all therapeutic proteins)",
                "Safety of immunization with live viral vaccines during or following therapy not studied; vaccination with live virus vaccines not recommended for at least 2 weeks prior to start of treatment, during treatment, and until immune recovery following last cycle of blinatumomab",
                "Fatal pancreatitis reported in combination with dexamethasone in clinical trials and post-marketing setting; evaluate patients who develop signs and symptoms of pancreatitis; management of pancreatitis may require either temporary interruption or discontinuation of blinatumomab and dexamethasone",
                "Benzyl alcohol preservative may cause serious adverse reactions (eg, gasping syndrome) in pediatrics; gasping syndrome is CNS depression, metabolic acidosis, and gasping respirations; consider total benzyl alcohol metabolic load contains 7.4 mg of benzyl alcohol; minimum benzyl alcohol amount which adverse reactions occur is unknown"
            ],
            "specific": [
                {
                    "type": "Possible drug interactions",
                    "description": [
                        "No formal drug interaction studies have been conducted  Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes",
                        "The highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the second cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index",
                        "In these patients, monitor for toxicity (eg, warfarin) or drug concentrations (eg, cyclosporine)",
                        "Adjust the dose of the concomitant drug as needed"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, blinatumomab.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sirolimus",
            "description": {
                "common": "blinatumomab increases levels of sirolimus by decreasing metabolism. Avoid or Use Alternate Drug. Treatment initiation causes transient release of cytokines that may suppress CYP450 enzymes; highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the 2nd cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "blinatumomab increases levels of carbamazepine by decreasing metabolism. Modify Therapy/Monitor Closely. Treatment initiation causes transient release of cytokines that may suppress CYP450 enzymes; highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the 2nd cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonidine",
            "description": {
                "common": "blinatumomab increases levels of clonidine by decreasing metabolism. Modify Therapy/Monitor Closely. Treatment initiation causes transient release of cytokines that may suppress CYP450 enzymes; highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the 2nd cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "blinatumomab increases levels of cyclosporine by decreasing metabolism. Modify Therapy/Monitor Closely. Treatment initiation causes transient release of cytokines that may suppress CYP450 enzymes; highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the 2nd cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and blinatumomab both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "disopyramide",
            "description": {
                "common": "blinatumomab increases levels of disopyramide by decreasing metabolism. Modify Therapy/Monitor Closely. Treatment initiation causes transient release of cytokines that may suppress CYP450 enzymes; highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the 2nd cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethosuximide",
            "description": {
                "common": "blinatumomab increases levels of ethosuximide by decreasing metabolism. Modify Therapy/Monitor Closely. Treatment initiation causes transient release of cytokines that may suppress CYP450 enzymes; highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the 2nd cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "blinatumomab increases levels of fosphenytoin by decreasing metabolism. Modify Therapy/Monitor Closely. Treatment initiation causes transient release of cytokines that may suppress CYP450 enzymes; highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the 2nd cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, blinatumomab.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "blinatumomab increases levels of phenobarbital by decreasing metabolism. Modify Therapy/Monitor Closely. Treatment initiation causes transient release of cytokines that may suppress CYP450 enzymes; highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the 2nd cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "blinatumomab increases levels of phenytoin by decreasing metabolism. Modify Therapy/Monitor Closely. Treatment initiation causes transient release of cytokines that may suppress CYP450 enzymes; highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the 2nd cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "blinatumomab increases levels of primidone by decreasing metabolism. Modify Therapy/Monitor Closely. Treatment initiation causes transient release of cytokines that may suppress CYP450 enzymes; highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the 2nd cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinidine",
            "description": {
                "common": "blinatumomab increases levels of quinidine by decreasing metabolism. Modify Therapy/Monitor Closely. Treatment initiation causes transient release of cytokines that may suppress CYP450 enzymes; highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the 2nd cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinine",
            "description": {
                "common": "blinatumomab increases levels of quinine by decreasing metabolism. Modify Therapy/Monitor Closely. Treatment initiation causes transient release of cytokines that may suppress CYP450 enzymes; highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the 2nd cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and blinatumomab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "blinatumomab increases levels of tacrolimus by decreasing metabolism. Modify Therapy/Monitor Closely. Treatment initiation causes transient release of cytokines that may suppress CYP450 enzymes; highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the 2nd cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "theophylline",
            "description": {
                "common": "blinatumomab increases levels of theophylline by decreasing metabolism. Modify Therapy/Monitor Closely. Treatment initiation causes transient release of cytokines that may suppress CYP450 enzymes; highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the 2nd cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "trastuzumab, blinatumomab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, blinatumomab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and blinatumomab both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valproic acid",
            "description": {
                "common": "blinatumomab increases levels of valproic acid by decreasing metabolism. Modify Therapy/Monitor Closely. Treatment initiation causes transient release of cytokines that may suppress CYP450 enzymes; highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the 2nd cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Pyrexia",
            "percent": "55-91"
        },
        {
            "name": "Infusion related reaction",
            "percent": "30-77"
        },
        {
            "name": "Other pathogen infections",
            "percent": "28-39"
        },
        {
            "name": "Headache",
            "percent": "23-36"
        },
        {
            "name": "Tremor",
            "percent": "31"
        },
        {
            "name": "Neutropenia",
            "percent": "16-31"
        },
        {
            "name": "Chills",
            "percent": "15-28"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "25"
        },
        {
            "name": "Nausea",
            "percent": "25"
        },
        {
            "name": "Peripheral edema",
            "percent": "25"
        },
        {
            "name": "Hypokalemia",
            "percent": "23"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "10-21"
        },
        {
            "name": "Tremor",
            "percent": "20"
        },
        {
            "name": "Constipation",
            "percent": "20"
        },
        {
            "name": "Diarrhea",
            "percent": "20"
        },
        {
            "name": "Bacterial infections",
            "percent": "19"
        },
        {
            "name": "Cough",
            "percent": "13-19"
        },
        {
            "name": "Insomnia",
            "percent": "15-18"
        },
        {
            "name": "Decreased immunoglobulins",
            "percent": "18"
        },
        {
            "name": "Fatigue",
            "percent": "17"
        },
        {
            "name": "Rash",
            "percent": "12-16"
        },
        {
            "name": "Dyspnea",
            "percent": "15"
        },
        {
            "name": "Abdominal pain",
            "percent": "15"
        },
        {
            "name": "Neutropenia",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "15"
        },
        {
            "name": "or more",
            "percent": "9-15"
        },
        {
            "name": "Hypertransaminasemia",
            "percent": "10-14"
        },
        {
            "name": "Dizziness",
            "percent": "12-14"
        },
        {
            "name": "Back pain",
            "percent": "9-14"
        },
        {
            "name": "Leukopenia",
            "percent": "14"
        },
        {
            "name": "Hypotension",
            "percent": "14"
        },
        {
            "name": "Bacterial infectious disorders",
            "percent": "14"
        },
        {
            "name": "Cytokine release syndrome",
            "percent": "12-14"
        },
        {
            "name": "Arrhythmia",
            "percent": "13"
        },
        {
            "name": "Vomiting",
            "percent": "11-13"
        },
        {
            "name": "Viral infections",
            "percent": "12"
        },
        {
            "name": "Pain in extremity",
            "percent": "12"
        },
        {
            "name": "Hypomagnesemia",
            "percent": "12"
        },
        {
            "name": "Increased ALT",
            "percent": "12"
        },
        {
            "name": "Aphasia",
            "percent": "11"
        },
        {
            "name": "Increased AST",
            "percent": "11"
        },
        {
            "name": "Bone pain",
            "percent": "11"
        },
        {
            "name": "Hyperglycemia",
            "percent": "11"
        },
        {
            "name": "Increased weight",
            "percent": "11"
        },
        {
            "name": "Chest pain",
            "percent": "11"
        },
        {
            "name": "Cytokine release syndrome",
            "percent": "11"
        },
        {
            "name": "Hypotension",
            "percent": "10"
        },
        {
            "name": "Fungal infections",
            "percent": "10"
        },
        {
            "name": "Arthralgias",
            "percent": "10"
        },
        {
            "name": "Decreased appetite",
            "percent": "10"
        },
        {
            "name": "Increased weight",
            "percent": "10"
        },
        {
            "name": "Encephalopathy",
            "percent": "3"
        },
        {
            "name": "Leukopenia",
            "percent": "9"
        },
        {
            "name": "Grade",
            "percent": "9"
        },
        {
            "name": "or more",
            "percent": "8"
        },
        {
            "name": "Pneumonia",
            "percent": "7"
        },
        {
            "name": "Hypertension",
            "percent": "6"
        },
        {
            "name": "Sepsis",
            "percent": "3"
        },
        {
            "name": "Hypophosphatemia",
            "percent": "3-5"
        },
        {
            "name": "Infusion",
            "percent": "3"
        },
        {
            "name": "related reaction",
            "percent": "5"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "or more",
            "percent": "4"
        },
        {
            "name": "Decreased immunoglobulins",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "4"
        },
        {
            "name": "or more",
            "percent": "3"
        },
        {
            "name": "Headache",
            "percent": "4"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "or more",
            "percent": "2"
        },
        {
            "name": "Tremor",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "1"
        },
        {
            "name": "or more",
            "percent": null
        },
        {
            "name": "Encephalopathy",
            "percent": null
        },
        {
            "name": "Grade",
            "percent": null
        },
        {
            "name": "or more",
            "percent": null
        },
        {
            "name": "Arrhythmia",
            "percent": null
        },
        {
            "name": "Grade",
            "percent": null
        },
        {
            "name": "or more",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Grade",
            "percent": null
        },
        {
            "name": "or more",
            "percent": null
        },
        {
            "name": "Stomach pain",
            "percent": null
        },
        {
            "name": "Fatal pancreatitis",
            "percent": null
        },
        {
            "name": "Paresthesia",
            "percent": null
        }
    ]
}